JP2004516013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004516013A5 JP2004516013A5 JP2002514188A JP2002514188A JP2004516013A5 JP 2004516013 A5 JP2004516013 A5 JP 2004516013A5 JP 2002514188 A JP2002514188 A JP 2002514188A JP 2002514188 A JP2002514188 A JP 2002514188A JP 2004516013 A5 JP2004516013 A5 JP 2004516013A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- nucleic acid
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002491 angiogenic effect Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (36)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21955600P | 2000-07-20 | 2000-07-20 | |
| US22066400P | 2000-07-25 | 2000-07-25 | |
| US22062400P | 2000-07-25 | 2000-07-25 | |
| PCT/US2000/020710 WO2001009327A2 (en) | 1999-07-28 | 2000-07-28 | Method of preventing the injury or death of retinal cells and treating ocular diseases |
| US22269500P | 2000-08-02 | 2000-08-02 | |
| US09/643,657 US6642024B1 (en) | 1998-01-29 | 2000-08-17 | Guanylate-binding protein |
| PCT/US2000/023522 WO2001016319A2 (en) | 1999-08-31 | 2000-08-23 | Compositions and methods for the treatment of immune related diseases |
| PCT/US2000/023328 WO2001016318A2 (en) | 1999-09-01 | 2000-08-24 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US23097800P | 2000-09-07 | 2000-09-07 | |
| US66535000A | 2000-09-18 | 2000-09-18 | |
| US66461000A | 2000-09-18 | 2000-09-18 | |
| US24292200P | 2000-10-24 | 2000-10-24 | |
| US70923800A | 2000-11-08 | 2000-11-08 | |
| PCT/US2000/030952 WO2001049715A2 (en) | 2000-01-06 | 2000-11-08 | Methods and compositions for inhibiting neoplastic cell growth |
| PCT/US2000/030873 WO2001040465A2 (en) | 1999-11-30 | 2000-11-10 | Compositions and methods for the treatment of immune related diseases |
| PCT/US2000/032678 WO2001040466A2 (en) | 1999-12-01 | 2000-12-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PCT/US2000/034956 WO2001046420A2 (en) | 1999-12-23 | 2000-12-20 | Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
| US09/747,259 US6569645B2 (en) | 1999-05-14 | 2000-12-20 | IL-17 homologous polypeptides and therapeutic uses thereof |
| US09/767,609 US20020042367A1 (en) | 1997-11-25 | 2001-01-22 | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
| US79649801A | 2001-02-28 | 2001-02-28 | |
| PCT/US2001/006520 WO2001068848A2 (en) | 2000-03-01 | 2001-02-28 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PCT/US2001/006666 WO2001066740A2 (en) | 2000-03-03 | 2001-03-01 | Compositions and methods for the treatment of immune related diseases |
| US80270601A | 2001-03-09 | 2001-03-09 | |
| US80868901A | 2001-03-14 | 2001-03-14 | |
| US09/816,744 US6579520B2 (en) | 1998-05-15 | 2001-03-22 | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| US09/828,366 US20020010137A1 (en) | 1997-09-18 | 2001-04-05 | Methods and compositions for inhibiting neoplastic cell growth |
| US09/854,208 US7217412B2 (en) | 1998-05-15 | 2001-05-10 | IL-17C related mammalian cytokine polypeptides |
| US09/854,280 US7115398B2 (en) | 1998-05-15 | 2001-05-10 | IL-17 homologous polypeptides and therapeutic uses thereof |
| PCT/US2001/017092 WO2001092331A2 (en) | 2000-05-30 | 2001-05-25 | Compositions and methods for the treatment of immune related diseases |
| US09/866,028 US6642360B2 (en) | 1997-12-03 | 2001-05-25 | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
| US09/866,034 US20030170864A1 (en) | 2000-05-30 | 2001-05-25 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US09/870,574 US6551799B2 (en) | 1999-12-07 | 2001-05-30 | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| PCT/US2001/017443 WO2002016611A2 (en) | 2000-08-24 | 2001-05-30 | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| PCT/US2001/017800 WO2001093983A1 (en) | 2000-06-02 | 2001-06-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PCT/US2001/019692 WO2002000690A2 (en) | 2000-06-23 | 2001-06-20 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| PCT/US2001/021735 WO2002008284A2 (en) | 2000-07-20 | 2001-07-09 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008194764A Division JP2009039119A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194721A Division JP2009039118A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194678A Division JP2009039117A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2011173336A Division JP6033531B2 (ja) | 2000-07-20 | 2011-08-08 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004516013A JP2004516013A (ja) | 2004-06-03 |
| JP2004516013A5 true JP2004516013A5 (ru) | 2010-07-15 |
Family
ID=56290165
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514188A Withdrawn JP2004516013A (ja) | 2000-07-20 | 2001-07-09 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194764A Withdrawn JP2009039119A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194678A Withdrawn JP2009039117A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194721A Withdrawn JP2009039118A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2011173336A Expired - Fee Related JP6033531B2 (ja) | 2000-07-20 | 2011-08-08 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008194764A Withdrawn JP2009039119A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194678A Withdrawn JP2009039117A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2008194721A Withdrawn JP2009039118A (ja) | 2000-07-20 | 2008-07-29 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| JP2011173336A Expired - Fee Related JP6033531B2 (ja) | 2000-07-20 | 2011-08-08 | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1309685A2 (ru) |
| JP (5) | JP2004516013A (ru) |
| AU (1) | AU2001271973A1 (ru) |
| CA (1) | CA2416538A1 (ru) |
| WO (1) | WO2002008284A2 (ru) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999060127A2 (en) | 1998-05-15 | 1999-11-25 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| AU738688B2 (en) | 1997-09-12 | 2001-09-27 | Apoxis Sa | Cysteine rich receptors-train |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US20030187196A1 (en) | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| US20030119113A1 (en) | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1621620A3 (en) * | 1999-09-01 | 2006-05-10 | Genetech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP2290081A3 (en) * | 1999-12-23 | 2012-08-01 | Genentech, Inc. | IL-17 homologous polypeptide and therapeutic uses thereof |
| US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| DE60126602T2 (de) * | 2000-04-21 | 2007-11-22 | Fuso Pharmaceutical Industries, Ltd. | Neue collectine |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP2168980A1 (en) * | 2000-06-23 | 2010-03-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
| EP1309620A2 (en) * | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| EP2792747A1 (en) * | 2000-06-23 | 2014-10-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US7265210B2 (en) | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
| US6630325B1 (en) * | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
| JP2004532609A (ja) | 2000-11-03 | 2004-10-28 | ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア | プロキネチシンポリペプチド、関連組成物および方法 |
| US7247717B2 (en) | 2000-11-14 | 2007-07-24 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01 |
| US7164007B2 (en) | 2001-06-20 | 2007-01-16 | Genentech, Inc. | Anti-PR020044 antibodies |
| EP1530590A2 (en) * | 2002-03-22 | 2005-05-18 | Bioxell S.p.a. | Triggering receptors expressed on myeloid cells (trem)-4 and -5 and uses thereof |
| JPWO2003083114A1 (ja) * | 2002-03-28 | 2005-08-04 | アステラス製薬株式会社 | アンジオポエチン関連増殖因子 |
| AU2003230874A1 (en) * | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| AU2003261911A1 (en) * | 2002-09-04 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Use of disease-associated gene |
| CA2497661A1 (en) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the diagnosis of immune related diseases using pro71061 |
| EP1585482A4 (en) * | 2002-09-25 | 2009-09-09 | Genentech Inc | NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS |
| CN102225194B (zh) | 2003-03-12 | 2014-07-16 | 健泰科生物技术公司 | Bv8和/或EG-VEGF促进造血的用途 |
| MXPA06000347A (es) | 2003-07-08 | 2006-03-28 | Genentech Inc | Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos. |
| US20100031378A1 (en) | 2008-08-04 | 2010-02-04 | Edwards Joel A | Novel gene disruptions, compositions and methods relating thereto |
| EP1734998A2 (en) | 2004-04-14 | 2006-12-27 | Genentech, Inc. | Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
| EP1781682B1 (en) | 2004-06-24 | 2013-03-13 | Mayo Foundation For Medical Education And Research | B7-h5, a costimulatory polypeptide |
| AU2005270078A1 (en) | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Compositions and methods for treatment of non-hodgkin's lymphoma |
| EP1789070B1 (en) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in neuronal function |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| WO2007056227A2 (en) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| EP2097455B1 (en) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Humanized anti-factor d antibodies |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| WO2009070243A2 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| US20090317400A1 (en) | 2008-05-05 | 2009-12-24 | Krzysztof Masternak | Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof |
| RU2553517C2 (ru) | 2008-05-06 | 2015-06-20 | Дженентек, Инк. | Варианты crig с созревшей аффинностью |
| FI2398902T3 (fi) | 2009-02-20 | 2023-11-28 | Astellas Pharma Inc | Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten |
| MX2011011729A (es) | 2009-05-05 | 2012-04-10 | Novimmune Sa | Anticuerpo anti il-17f y metodos de uso de los mismos. |
| TWI428142B (zh) | 2009-05-08 | 2014-03-01 | Genentech Inc | 人類化之抗－ｅｇｆｌ７抗體及其使用方法 |
| AT508569A1 (de) | 2009-07-23 | 2011-02-15 | Affiris Ag | Pharmaceutical compound |
| KR102126964B1 (ko) | 2009-11-11 | 2020-06-25 | 가니메드 파마슈티칼스 게엠베하 | 클라우딘 6 특이적 항체 |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| DK3026064T3 (en) | 2011-05-13 | 2019-01-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 |
| KR102077721B1 (ko) | 2011-07-01 | 2020-02-14 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| ES2915851T3 (es) | 2012-12-27 | 2022-06-27 | Ngm Biopharmaceuticals Inc | Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares |
| EP3747457A3 (en) * | 2013-01-17 | 2021-03-03 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| KR20160042438A (ko) | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
| CA2927592C (en) | 2013-10-28 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Fgf-19 variants for treating a fgf-19 dependent cancer or tumor |
| EP3097122B9 (en) | 2014-01-24 | 2020-11-11 | NGM Biopharmaceuticals, Inc. | Antibodies binding beta klotho domain 2 and methods of use thereof |
| US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
| US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
| CA3082794A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methods for treatment of bile acid-related disorders |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| GB201906052D0 (en) * | 2019-04-30 | 2019-06-12 | Int Centre For Genetic Engineering And Biotechnology | Proteins with cardioprotective activity |
| JP7064179B2 (ja) | 2020-11-30 | 2022-05-10 | 富士電機株式会社 | 水分吸着材 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000032221A2 (en) * | 1998-12-01 | 2000-06-08 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| WO2000053756A2 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000053751A1 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2002532054A (ja) * | 1997-08-29 | 2002-10-02 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２９個のヒト分泌タンパク質 |
| EP1056847A2 (en) * | 1998-02-27 | 2000-12-06 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
| ES2312205T3 (es) * | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| WO1999050405A1 (en) * | 1998-03-31 | 1999-10-07 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| KR20010085792A (ko) * | 1998-09-14 | 2001-09-07 | 제넨테크, 인크. | 혈관형성 및 심혈관형성의 촉진 또는 억제 |
| KR100543857B1 (ko) * | 1999-09-01 | 2006-01-23 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
| EP1309620A2 (en) * | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
-
2001
- 2001-07-09 CA CA002416538A patent/CA2416538A1/en not_active Abandoned
- 2001-07-09 AU AU2001271973A patent/AU2001271973A1/en not_active Abandoned
- 2001-07-09 JP JP2002514188A patent/JP2004516013A/ja not_active Withdrawn
- 2001-07-09 EP EP01951036A patent/EP1309685A2/en not_active Withdrawn
- 2001-07-09 WO PCT/US2001/021735 patent/WO2002008284A2/en active Search and Examination
-
2008
- 2008-07-29 JP JP2008194764A patent/JP2009039119A/ja not_active Withdrawn
- 2008-07-29 JP JP2008194678A patent/JP2009039117A/ja not_active Withdrawn
- 2008-07-29 JP JP2008194721A patent/JP2009039118A/ja not_active Withdrawn
-
2011
- 2011-08-08 JP JP2011173336A patent/JP6033531B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004516013A5 (ru) | ||
| EP0617126B1 (en) | Polypeptide capable of inhibiting the binding between human IL-6 and its receptor | |
| CN105143267B (zh) | 人pac1抗体 | |
| EP3760642A1 (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
| RU2183215C2 (ru) | Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| JP4308322B2 (ja) | インターフェロンアルファ／ベータ受容体に対する抗体 | |
| WO2006046661A1 (ja) | インターロイキン－６阻害剤 | |
| JP2020509737A5 (ru) | ||
| AU750296B2 (en) | Antibodies against SEMP1, methods for their production and uses thereof | |
| JP2004513876A (ja) | 抗−腫瘍剤としてのｔａｃｉ | |
| BG107613A (bg) | Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена | |
| TW202108630A (zh) | ETA抗體與TGF-β Trap的融合蛋白質，以及其藥物組合物和應用 | |
| EP1283217B1 (en) | Antibodies against the IL-8 receptor, and their therapeutic uses | |
| TW416960B (en) | Reshaped human antibody to human interleukin-8 | |
| JP2003530871A (ja) | インテグリン／接着因子アンタゴニスト | |
| KR100277769B1 (ko) | 항-파스 재조합 항체 및 이에 대한 디엔에이 | |
| CN116917326A (zh) | 抗her-2/trop-2构建体及其用途 | |
| KR102669444B1 (ko) | Etar 항체 및 이의 약학 조성물 및 용도 | |
| CA3180251A1 (en) | Cytokine conjugates | |
| WO2023222035A1 (zh) | 抗tigit抗体与il2的融合蛋白或其变体及其应用 | |
| US20230391863A1 (en) | Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof | |
| CA3232777A1 (en) | Novel interferon variants and bifunctional fusion molecules thereof | |
| WO2020248967A1 (zh) | Eta抗体与bnp的融合蛋白质，以及其药物组合物和应用 | |
| JP7300008B2 (ja) | 低免疫原性かつ低ＡＤＣＣ／ＣＤＣ機能の抗ＴＮＦ－αヒト化モノクローナル抗体ＴＣＸ０６０およびその使用 |